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AbstRAct
Objective To update the European League Against 
Rheumatism (EULAR) recommendations for the 
pharmacological treatment of psoriatic arthritis (PsA).
Methods According to the EULAR standardised 
operating procedures, a systematic literature review 
was followed by a consensus meeting to develop this 
update involving 28 international taskforce members 
in May 2019. Levels of evidence and strengths of 
recommendations were determined.
Results The updated recommendations comprise 
6 overarching principles and 12 recommendations. 
The overarching principles address the nature of 
PsA and diversity of both musculoskeletal and 
non- musculoskeletal manifestations; the need for 
collaborative management and shared decision- making 
is highlighted. The recommendations provide a treatment 
strategy for pharmacological therapies. Non- steroidal 
anti- inflammatory drugs and local glucocorticoid 
injections are proposed as initial therapy; for patients 
with arthritis and poor prognostic factors, such as 
polyarthritis or monoarthritis/oligoarthritis accompanied 
by factors such as dactylitis or joint damage, rapid 
initiation of conventional synthetic disease- modifying 
antirheumatic drugs is recommended. If the treatment 
target is not achieved with this strategy, a biological 
disease- modifying antirheumatic drugs (bDMARDs) 
targeting tumour necrosis factor (TNF), interleukin 
(IL)- 17A or IL-12/23 should be initiated, taking into 
account skin involvement if relevant. If axial disease 
predominates, a TNF inhibitor or IL- 17A inhibitor should 
be started as first- line disease- modifying antirheumatic 
drug. Use of Janus kinase inhibitors is addressed 
primarily after bDMARD failure. Phosphodiesterase-4 
inhibition is proposed for patients in whom these other 
drugs are inappropriate, generally in the context of 
mild disease. Drug switches and tapering in sustained 
remission are addressed.
Conclusion These recommendations provide 
stakeholders with an updated consensus on the 
pharmacological management of PsA, based on a 
combination of evidence and expert opinion.
InTROduCTIOn
Psoriatic arthritis (PsA) is a disease with heteroge-
neous manifestations in patients who have manifest 
or latent psoriasis. It comprises both musculoskel-
etal as well as non- musculoskeletal manifestations; 
the latter particularly include the skin and the nails, 
but also potentially the gut (inflammatory bowel 
disease) or the eyes (uveitis). Active chronic PsA 
also associates with cardiovascular, psychological 
and metabolic comorbidities,1–7 which, together 
with the musculoskeletal manifestations, impose a 
significant patient burden with impact on quality of 
life and also accelerated mortality.8–10
The day- to- day management of patients with 
PsA includes non- pharmacological as well as 
pharmacological interventions. The number of 
disease- modifying antirheumatic drugs (DMARDs) 
indicated for PsA has increased during the last 
decade. The armamentarium now includes not only 
conventional synthetic DMARDs (csDMARDs) 
such as methotrexate (MTX), sulfasalazine and 
leflunomide and tumour necrosis factor inhibitors 
(TNFi), but also other targeted biological agents 
(bDMARDs) aimed at different cytokines, such as 
TNF, interleukin (IL)-12/23 and IL- 17A, as well 
as targeted synthetic DMARDs (tsDMARDs) that 
inhibit phosphodiesterase-4 (PDE4) or Janus kinases 
(JAKs).11–16 These multiple newer drugs have 
been investigated well in short- term, randomised 
controlled trials using placebo as comparator for 
reasons of drug approval. However, comparative 
research of different drugs, important for clinical 
practice, is rather sparse and clinicians need some 
guidance in decision- making.17–20
The European League Against Rheumatism 
(EULAR) developed recommendations for the 
pharmacological management of PsA in 2011 and 
updated them in 2015. These recommendations 
had their main focus on the musculoskeletal aspects 
of the disease and addressed the entire spectrum of 
PsA severity since they pertained to patients with 
very mild to very severe PsA.12 15 18 In this rapidly 
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evolving field, a further update of the 2015 recommendations 
became necessary to accommodate newly obtained evidence and 
insights. The objective of this taskforce, therefore, was to update 
the EULAR recommendations for the management of PsA with 
non- topical, pharmacological therapies.
MeTHOds
The updated EULAR standardised operating procedures were 
applied.21 In October 2018, a steering group consisting of five 
rheumatologists, a fellow, a patient research partner and a health 
professional defined the questions that were to be addressed 
through a systematic literature review (SLR). The SLR was 
performed between October 2018 and May 2019, for the years 
2015–2018, and analysed the efficacy in both musculoskeletal 
manifestations as well as the skin and nails in patients with PsA.1 
Of note, the SLR was not centred on skin psoriasis trials, and 
these trials are not reviewed systematically or alluded to system-
atically here. Where relevant and based on expert opinion, data 
made available after the end of the SLR were also integrated. 
In May 2019, the steering group as well as the taskforce met to 
integrate available information on disease management in PsA 
into practical recommendations. The taskforce consisted of 28 
persons from 15 European countries with 15 different health-
care systems: 21 rheumatologists, 2 people affected with PsA, 
1 health professional, 1 dermatologist and 3 rheumatology 
fellows/trainees. The taskforce comprised more than 30% new 
members compared with 2015.
The SLR informed the recommendations. However, the 
process was not only evidence- based but also experience- based 
and consensus- based, in line with the three- tier principles of 
evidence- based medicine that include clinical science (trials), 
patients’ perceptions and expectations, and physicians’ experi-
ences. Benefit to cost ratios were taken into consideration when 
discussing prioritisation of drugs, since new effective treatments 
impose a significant burden on the healthcare budgets of EULAR 
and non- EULAR countries. Treatment guidance should there-
fore not only include considerations about safety and efficacy 
but should also focus on cost of treatment, in particular when 
different therapies have similar efficacy and safety data.
The results of the SLR were presented to the taskforce during 
a face- to- face meeting in May 2019, alongside the 2015 recom-
mendations and proposals for changes to these recommenda-
tions prepared by the steering committee. Each recommendation 
was discussed in detail both in smaller (breakout) groups and 
in plenary sessions until consensus was reached. For changes to 
existing recommendations against which no new evidence has 
accrued since the last update, a ≥75% vote by the taskforce 
was mandated in order to prevent new taskforces from refor-
mulating without major reasoning what had previously been 
developed based on the evidence presented at that point in time. 
If this majority was not reached, the recommendation was not 
changed. New recommendations were formulated and then 
accepted if ≥75% of the members agreed; if this agreement was 
not reached, the recommendation was reworded and subjected 
to a renewed vote for which a ≥67% majority was required. If 
this was not achieved, the wording underwent a next round of 
discussion and the new phrasing was approved if >50% of the 
taskforce members voted for it.
After the face- to- face meeting, the taskforce members were 
provided with the category of evidence and grade of recommen-
dation for each item, based on the Oxford Evidence Based Medi-
cine categorisation, as per the EULAR procedures.21 22 Then 
an anonymised, email- based voting on the level of agreement 
among the taskforce members was performed on a 0–10 scale 
(with 10 meaning full agreement) allowing calculation of mean 
levels of agreement.
ResulTs
The recommendations are shown in table 1, and the modifica-
tions compared with the previous recommendations are shown 
in table 2. These recommendations address non- topical pharma-
cological treatments with a main focus on musculoskeletal mani-
festations. As before, the updated recommendations are targeted 
at various stakeholders, such as (1) experts involved in the care 
of patients with PsA, particularly rheumatologists and other 
health professionals (such as rheumatology nurses), but also 
general practitioners, dermatologists and other specialists; (2) 
people with PsA who can use these recommendations for infor-
mation on current therapies, treatment strategies and opportu-
nities; and (3) other stakeholders which include government and 
hospital officials, patient organisations, regulatory agencies and 
reimbursement institutions.
Overarching principles
These refer to principles of a generic nature (table 1). Note 
that optimal management of patients with PsA also requires 
non- pharmacological strategies such as patient education and 
regular physical exercise and may also require topical medi-
cation (in particular for skin psoriasis). The non- systemic and 
non- pharmacological therapies are not addressed in the present 
document.23
The overarching principles remained mostly unchanged 
compared with 2015 (table 2). Principle A refers to the hetero-
geneous and potentially severe nature of PsA, and principle B 
addresses the importance of shared decision- making with the 
patient, but also costs. Indeed, while efficacy and safety are 
considered to be the key drivers of the decision- making process, 
the committee noted that cost of treatment should also be taken 
into account. Modern DMARDs are expensive and unaffordable 
to many patients in less- affluent countries, but also in affluent 
countries social security systems may preclude provision of 
certain drugs to a significant proportion of patients, or request 
clinically unacceptable conditions (such as high disease activity 
or limitation of important agents to a maximum number) for 
cost reasons. Nevertheless, EULAR proclaims that all patients 
with active and/or severe (not necessarily highly active) PsA 
should have the right to be prescribed the treatment they need 
to optimise their quality of life. Of note, recently, costs of some 
drugs have decreased considerably through access to biosimi-
lars and bio- originator repricing, but these advantages are not 
conveyed in all countries alike.
The pivotal status of the rheumatologist as the main caregiver 
for people with PsA is dealt with in principle C. Rheumatologists 
possess the optimal depth and breadth of experience regarding 
the use of all types of DMARDs, including efficacy outcomes, 
risk assessment and knowledge of comorbidities. The role of 
nurses and other health professionals in the management of PsA, 
in relation to principles A and B, was addressed by the taskforce. 
While rheumatologists are the principal physicians in the care 
of PsA, in some countries rheumatology nurses may prescribe 
medication and are the main healthcare givers for patients. On 
the other hand, in certain areas of the world, rheumatology 
training is not sufficiently available and other experts may care 
for patients with PsA, hence the term ‘primarily’. Where there 
is a lack of rheumatologists, the taskforce recognised the contri-
bution of other physicians with appropriate rheumatological 
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Table 1 2019 EULAR recommendations for the pharmacological management of psoriatic arthritis, with levels of evidence, grade of 
recommendations and level of agreement
Overarching principles
level of agreement, 
mean (sd)
A Psoriatic arthritis is a heterogeneous and potentially severe disease, which may require multidisciplinary treatment. 9.9 (0.4)
b treatment of psoriatic arthritis patients should aim at the best care and must be based on a shared decision between the patient and the rheumatologist, 
considering efficacy, safety and costs.
9.8 (0.5)
c Rheumatologists are the specialists who should primarily care for the musculoskeletal manifestations of patients with psoriatic arthritis; in the presence of 
clinically significant skin involvement, a rheumatologist and a dermatologist should collaborate in diagnosis and management.
9.8 (0.7)
D the primary goal of treating patients with psoriatic arthritis is to maximise health- related quality of life, through control of symptoms, prevention of structural 
damage, normalisation of function and social participation; abrogation of inflammation is an important component to achieve these goals.
9.9 (0.4)
E In managing patients with psoriatic arthritis, consideration should be given to each musculoskeletal manifestation and treatment decisions made accordingly. 9.9 (0.3)
F When managing patients with psoriatic arthritis, non- musculoskeletal manifestations (skin, eye and gastrointestinal tract) should be taken into account; 







level of agreement, 
mean (sd)
1 treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular 
disease activity assessment and appropriate adjustment of therapy.
1b A 9.4 (1.0)
2 Non- steroidal anti- inflammatory drugs may be used to relieve musculoskeletal signs and symptoms. 1b A 9.6 (0.8)
3 Local injections of glucocorticoids should be considered as adjunctive therapy in psoriatic arthritis*; systemic 




4 In patients with polyarthritis, a csDMARD should be initiated* rapidly†, with methotrexate preferred in those 




5 In patients with monoarthritis or oligoarthritis, particularly with poor prognostic factors such as structural 
damage, high erythrocyte sedimentation rate/c reactive protein, dactylitis or nail involvement, a csDMARD 
should be considered.
4 c 9.3 (1.0)
6 In patients with peripheral arthritis and an inadequate response to at least one csDMARD, therapy with a 
bDMARD should be commenced; when there is relevant skin involvement, an IL-17 inhibitor or IL-12/23 
inhibitor may be preferred.
1b b 9.4 (1.1)
7 In patients with peripheral arthritis and an inadequate response to at least one csDMARD and at least one 
bDMARD, or when a bDMARD is not appropriate, a JAK inhibitor may be considered.
1b b 9.2 (1.3)
8 In patients with mild disease* and an inadequate response to at least one csDMARD†, in whom neither a 




9 In patients with unequivocal enthesitis and insufficient response to NsAIDs or local glucocorticoid injections, 
therapy with a bDMARD should be considered.
1b b 9.3 (0.9)
10 In patients with predominantly axial disease which is active and has insufficient response to NsAIDs, therapy 
with a bDMARD should be considered, which according to current practice is a tNF inhibitor; when there is 
relevant skin involvement, IL-17 inhibitor may be preferred.
1b b 9.7 (0.6)
11 In patients who fail to respond adequately to, or are intolerant of a bDMARD, switching to another bDMARD or 




12 In patients in sustained remission, cautious tapering of DMARDs may be considered. 4 c 9.5 (0.9)
the level of agreement was computed on a 0–10 scale.
csDMARDs include methotrexate, sulfasalazine or leflunomide; bDMARDs include here tNF inhibitors (both original and biosimilars) and drugs targeting the IL-17 and IL-12/23 
pathways.
bDMARDs, biological disease- modifying antirheumatic drugs; csDMARDs, conventional synthetic disease- modifying antirheumatic drugs; DMARDs, disease- modifying 
antirheumatic drugs; EULAR, European League Against Rheumatism; IL, interleukin; JAK, Janus kinase; NsAIDs, non- steroidal anti- inflammatory drugs; PDE4, 
phosphodiesterase-4; tNF, tumour necrosis factor.
expertise and added this point also into the research agenda 
(table 3).
The treatment target is elimination of inflammation and opti-
misation of quality of life (principle D) (see table 1 and the 2015 
update for detailed information).18 The importance of fatigue 
was also highlighted.1 5 7 10 24
The last two overarching principles refer to treatment strategy 
and have been modified. Principle E is a new overarching prin-
ciple which reiterates the importance of all musculoskeletal 
manifestations in patients with PsA: this not only relates to 
peripheral arthritis but also enthesitis, tenosynovitis, tendinitis, 
dactylitis and inflammatory axial disease.
Principle F (which in 2015 was principle E) now includes the 
term ‘non- musculoskeletal’, replacing the term ‘extra- articular’ 
manifestations, and refers to PsA- linked organ involvement, 
namely psoriasis, uveitis and inflammatory bowel disease. 
The term ‘extra- articular manifestations’ was considered 
unclear—for some it includes axial or entheseal symptoms, 
which was not intended in this context.25–27 Although all the 
non- musculoskeletal manifestations should be taken into 
account, psoriasis is of course the most frequent. Referring to 
comorbidities, aside from cardiovascular disease, depression is 
explicitly mentioned because of its frequency and impact on the 
patient.4 7 10 24 28 29 The list of comorbidities is not meant to be 
exhaustive and other comorbidities should also be considered.
Recommendations
Twelve recommendations were formulated or updated (tables 1 
and 2) and formed the basis of the management algorithm 
(figure 1). Table 1 provides the category of evidence, grade of 
recommendation and level of agreement for each of the points.17 
It must be borne in mind that the individual disease character-
istics—in line with the multidimensional nature of PsA—may 
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Table 2 comparison of the 2015 and 2019 recommendations
2019 (current) version Changes performed 2015 version
Overarching principles
A Psoriatic arthritis is a heterogeneous and potentially severe disease, which may 
require multidisciplinary treatment.
Unchanged Psoriatic arthritis is a heterogeneous and potentially severe disease, which may require 
multidisciplinary treatment.
b treatment of psoriatic arthritis patients should aim at the best care and must 
be based on a shared decision between the patient and the rheumatologist, 
considering efficacy, safety and costs.
Unchanged treatment of psoriatic arthritis patients should aim at the best care and must be based 
on a shared decision between the patient and the rheumatologist, considering efficacy, 
safety and costs.
c Rheumatologists are the specialists who should primarily care for the 
musculoskeletal manifestations of patients with psoriatic arthritis; in the presence 
of clinically significant skin involvement, a rheumatologist and a dermatologist 
should collaborate in diagnosis and management.
Unchanged Rheumatologists are the specialists who should primarily care for the musculoskeletal 
manifestations of patients with psoriatic arthritis; in the presence of clinically significant 
skin involvement, a rheumatologist and a dermatologist should collaborate in diagnosis 
and management.
D the primary goal of treating patients with psoriatic arthritis is to maximise health- 
related quality of life, through control of symptoms, prevention of structural 
damage, normalisation of function and social participation; abrogation of 
inflammation is an important component to achieve these goals.
Unchanged the primary goal of treating patients with psoriatic arthritis is to maximise health- 
related quality of life, through control of symptoms, prevention of structural damage, 
normalisation of function and social participation; abrogation of inflammation is an 
important component to achieve these goals.
E In managing patients with psoriatic arthritis, consideration should be given to each 
musculoskeletal manifestation and treatment decisions made accordingly.
New Not applicable.
F When managing patients with psoriatic arthritis, non- musculoskeletal 
manifestations (skin, eye and gastrointestinal tract) should be taken into account; 
comorbidities such as metabolic syndrome, cardiovascular disease or depression 
should also be considered.
Rephrased When managing patients with psoriatic arthritis, extra- articular manifestations, 
metabolic syndrome, cardiovascular disease and other comorbidities should be taken 
into account.
Recommendations
1 treatment should be aimed at reaching the target of remission or, alternatively, low 
disease activity, by regular disease activity assessment and appropriate adjustment 
of therapy.
Rephrased treatment should be aimed at reaching the target of remission or, alternatively, 
minimal/low disease activity, by regular monitoring and appropriate adjustment of 
therapy.
2 Non- steroidal anti- inflammatory drugs may be used to relieve musculoskeletal 
signs and symptoms.
Rephrased In patients with psoriatic arthritis, non- steroidal anti- inflammatory drugs may be used 
to relieve musculoskeletal signs and symptoms.
3 Local injections of glucocorticoids should be considered as adjunctive therapy in 
psoriatic arthritis; systemic glucocorticoids may be used with caution at the lowest 
effective dose.
Renumbered Local injections of glucocorticoids should be considered as adjunctive therapy in 
psoriatic arthritis; systemic glucocorticoids may be used with caution at the lowest 
effective dose.
4 In patients with polyarthritis, a csDMARD should be initiated rapidly, with 
methotrexate preferred in those with relevant skin involvement.
Modified In patients with peripheral arthritis, particularly in those with many swollen joints, 
structural damage in the presence of inflammation, high EsR/cRP and/or clinically 
relevant extra- articular manifestations, csDMARDs should be considered at an early 
stage, with methotrexate preferred in those with relevant skin involvement.
5 In patients with monoarthritis or oligoarthritis, particularly with poor prognostic 
factors such as structural damage, high erythrocyte sedimentation rate/c reactive 
protein, dactylitis or nail involvement, a csDMARD should be considered.
New Not applicable but partly covered in the recommendation above.
6 In patients with peripheral arthritis and an inadequate response to at least one 
csDMARD, therapy with a bDMARD should be commenced; when there is relevant 
skin involvement, an IL-17 inhibitor or IL-12/23 inhibitor may be preferred.
Modified and merged In patients with peripheral arthritis and an inadequate response to at least one 
csDMARD, therapy with a bDMARD, usually a tNF inhibitor, should be commenced.
In patients with peripheral arthritis and an inadequate response to at least one 
csDMARD, in whom tNF inhibitors are not appropriate, bDMARDs targeting IL-12/23 or 
IL-17 pathways may be considered.
7 In patients with peripheral arthritis and an inadequate response to at least one 
csDMARD and at least one bDMARD, or when a bDMARD is not appropriate, a JAK 
inhibitor may be considered.
New Not applicable.
8 In patients with mild disease and an inadequate response to at least one csDMARD, 
in whom neither a bDMARD nor a JAK inhibitor is appropriate, a PDE4 inhibitor 
may be considered.
Modified In patients with peripheral arthritis and an inadequate response to at least one 
csDMARD, in whom bDMARDs are not appropriate, a targeted synthetic DMARD such 
as a PDE4 inhibitor may be considered.
9 In patients with unequivocal enthesitis and insufficient response to NsAIDs or local 
glucocorticoid injections, therapy with a bDMARD should be considered.
Modified In patients with active enthesitis and/or dactylitis and insufficient response to NsAIDs 
or local glucocorticoid injections, therapy with a bDMARD should be considered, which 
according to current practice is a tNF inhibitor.
10 In patients with predominantly axial disease which is active and has insufficient 
response to NsAIDs, therapy with a bDMARD should be considered, which 
according to current practice is a tNF inhibitor; when there is relevant skin 
involvement, IL-17 inhibitor may be preferred.
Modified In patients with predominantly axial disease that is active and has insufficient response 
to NsAIDs, therapy with a bDMARD should be considered, which according to current 
practice is a tNF inhibitor.
11 In patients who fail to respond adequately to, or are intolerant of a bDMARD, 
switching to another bDMARD or tsDMARD should be considered*, including one 
switch within a class†.
Modified In patients who fail to respond adequately to a bDMARD, switching to another 
bDMARD should be considered, including switching between tNF inhibitors.
12 In patients in sustained remission, cautious tapering of DMARDs may be 
considered.
New Not applicable.
csDMARDs include methotrexate, sulfasalazine or leflunomide; bDMARDs include here tNF inhibitors (both original and biosimilars) and drugs targeting the IL-17 and IL-12/23 pathways.
bDMARDs, biological disease- modifying antirheumatic drugs; cRP, c reactive protein; csDMARDs, conventional synthetic disease- modifying antirheumatic drugs; DMARDs, disease- modifying antirheumatic drugs; 
EsR, erythrocyte sedimentation rate; IL, interleukin; JAK, Janus kinase; NsAIDs, non- steroidal anti- inflammatory drugs; PDE4, phosphodiesterase-4; tNF, tumour necrosis factor; tsDMARDs, targeted synthetic disease- 
modifying antirheumatic drugs.
respond differently to specific therapies and thus require use 
of distinct assessment instruments for each manifestation. 
This variability as well as contraindications and risks must be 
taken into account, and thus the balance between efficacy and 
safety is always dependent on the characteristics of the indi-
vidual patient. Both table 1 and figure 1 synthesise the recom-
mendations in an abbreviated way, and the accompanying text 
provides more detailed information about the evidence and the 
discussion process and should be regarded as integral to the 
recommendations.
Recommendation 1: treatment should be aimed at reaching the 
target of remission or, alternatively, low disease activity, by regular 
disease activity assessment and appropriate adjustment of therapy.
This recommendation puts forward the importance of a treat- 
to- target (T2T) approach. The T2T strategy, which comprises 
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Table 3 Research agenda for PsA
Theme Research questions
Responsibility Role of the rheumatologist vs other specialists in the management of PsA.
Diagnosis Defining screening strategies for PsA among patients with psoriasis: is screening needed, and if so in which populations, how and when?
criteria for early diagnosis of PsA, including predictors for the development of PsA in patients with skin psoriasis.
Diagnosis of axial involvement.
Prognosis Defining prognostic factors related to risk of progressive disease, structural damage and bad functional outcome in early (and established) PsA.
Predicting response to treatment (predicting response to NsAIDs, to csDMARDs, to the different bDMARDs, to tsDMARDs).
Assessment of spinal disease: defining the similarities and differences with spondyloarthritis.
Pathophysiology Defining the relationship between inflammation and structural damage in PsA.
Exploring juvenile PsA: is it different from adult- onset PsA?
Identification of new therapeutic targets.
Pathogenetic pathways leading to arthritis, dactylitis, enthesitis, tenosynovitis, tendinitis, axial disease and skin disease; similarities and differences.
Genetics of PsA.
Phenotypes Entheseal PsA: overlap with widespread pain syndrome and role of imaging in the diagnosis.
Axial PsA: definition and role of imaging in the diagnosis.
biomarkers Determining biomarkers related to early diagnosis, damage, prognosis and treatment response.
treatment strategy Assessing efficacy and safety of combinations of csDMARDs compared with csDMARD monotherapy (with and without low- dose glucocorticoids).
Assessing efficacy and safety of combinations of csDMARDs with biologics compared with biologics monotherapy.
comparing efficacy and safety of methotrexate vs biological monotherapy vs their combination in early PsA.
Evaluating the need for early treatment in PsA: Who should be treated with csDMARDs? When to start treatment with DMARDs?
switching and cycling between drugs.
therapeutic drug monitoring to optimise cost and to support switching between bDMARDs within the same class or to a different mode of action.
Efficacy in oligoarticular rather than in polyarticular disease.
Efficacy in axial disease.
strategy trials.
Outcomes composite scores in PsA and assessment of treatment outcomes.
Usefulness of separate assessment of multiple scores limited to some specific domains in PsA.
Axial involvement in PsA.
Fatigue in PsA.
csDMARDs Efficacy of methotrexate in PsA, including for enthesitis.
Efficacy of csDMARDs for dactylitis.
Efficacy and safety of combination therapy of csDMARDs.
strategy of csDMARDs before bDMARDs/tsDMARDs.
bDMARDs and tsDMARDs Efficacy of combining csDMARDs with bDMARDs, compared with bDMARD monotherapy and with csDMARD monotherapy.
comparison of apremilast with methotrexate.
timing to start bDMARDs.
Duration of biological therapy, including addressing bDMARD dose reduction or discontinuation.
Head- to- head trials.
structural data for apremilast.
How to identify the right bDMARD for the right patient phenotype.
comparative safety of bDMARDs in PsA.
Differential effects of bDMARDs on comorbidities such as metabolic syndrome.
systemic glucocorticoids Assessing the risk of skin flares related to systemic glucocorticoids and in particular at low doses.
Assessing the benefit to risk ratio of long- term glucocorticoid therapy.
switches strategies after failures of bDMARDs other than tNFi.
Repeat switching within a bDMARD class.
comorbidities cardiovascular disease and metabolic syndrome in PsA and links with disease activity.
Alcohol in PsA in particular when treating with methotrexate.
cardiovascular risk and DMARDs in PsA.
bDMARDs, biological disease- modifying antirheumatic drugs; csDMARDs, conventional synthetic disease- modifying antirheumatic drugs; DMARDs, disease- modifying antirheumatic drugs; NsAIDs, 
non- steroidal anti- inflammatory drugs; PsA, psoriatic arthritis; tNFi, tumour necrosis factor inhibitor; tsDMARDs, targeted synthetic disease- modifying antirheumatic drugs.
definition of a distinct target as well as adherence to rules for 
monitoring and therapeutic adjustment, is well validated partic-
ularly in rheumatoid arthritis.30 The T2T recommendations for 
PsA have been updated recently.31 32 In line with these recom-
mendations, this point has been slightly rephrased and now 
states clearly that remission or low disease activity should be 
targeted, with the deletion of the previously stated term of 
minimal disease activity (which refers to a score allowing the 
assessment of low disease activity rather than to a target).33 34 
Remission in PsA is difficult to define.33 Remission should be 
seen as abrogation of inflammation.
Recommendation 2: Non-steroidal anti-inflammatory drugs may be 
used to relieve musculoskeletal signs and symptoms.
As in previous versions the taskforce continues to recommend 
the use of an non- steroidal anti- inflammatory drug (NSAID) to 
relieve symptoms.18 The benefit to risk ratio of NSAIDs must 
always be considered carefully, especially in this population with 
frequent cardiovascular comorbidities.
The taskforce noted that, in contrast to rheumatoid arthritis, in 
mild synovitis in PsA or for non- synovial features including axial 
symptoms, NSAIDs alone may be sufficient to control symptoms, 
especially with local glucocorticoid injections (see recommenda-
tion 3). There are little data regarding the efficacy of NSAIDs in 
enthesitis. In patients with peripheral arthritis, NSAIDs should 
be combined rapidly with DMARDs if needed (see also recom-
mendations 4 and 5). NSAIDs have not shown any efficacy 
in skin psoriasis. When peripheral arthritis is present, NSAID 
monotherapy without DMARDs should not exceed 1 month if 
disease activity persists, and other treatment possibilities should 
be considered. When axial or entheseal involvement dominates 
the clinical picture, the duration of NSAID therapy might be 
prolonged up to 12 weeks, provided they have already induced 
relief by 4 weeks.35 If the treatment target is not achieved, other 
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Figure 1 the EULAR 2019 algorithm for treatment of PsA with pharmacological non- topical treatments. bDMARDs, biological disease- modifying 
antirheumatic drugs; EULAR, European League Against Rheumatism; IL-12/23i, interleukin-12/23 inhibitor; IL- 17i, interleukin-17 inhibitor; JAKi, Janus 
kinase inhibitor; NsAIDs, non- steroidal anti- inflammatory drugs; PDE4i, phosphodiesterase-4 inhibitor; PsA, psoriatic arthritis; tNFi, tumour necrosis 
factor inhibitor.
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therapies should be prescribed as detailed in the subsequent 
recommendations.
Recommendation 3: Local injections of glucocorticoids should be 
considered as adjunctive therapy in psoriatic arthritis; systemic 
glucocorticoids may be used with caution at the lowest effective 
dose.
This recommendation is unchanged compared with 2015 but 
has been reordered to better align with the different phases of 
treatment (figure 1).18 It has to be also noted that glucocorticoid 
therapy should be used for only a short period of time. The task-
force does not recommend the use of systemic glucocorticoids 
for axial disease.35
Recommendation 4: In patients with polyarthritis, a csDMARD 
should be initiated rapidly, with methotrexate preferred in those 
with relevant skin involvement.
The main change in recommendations 4 and 5 (together recom-
mendation 3 in 2015) is the separation of polyarticular versus 
oligoarticular joint involvement to ensure that the poorer prog-
nostic nature of polyarthritis is more strongly emphasised than 
this was done before. The taskforce defined polyarticular disease 
as five or more active (swollen) joints.36 Patients with polyartic-
ular disease should receive a csDMARD either as first- line drug 
or after only a short course of NSAIDs. ‘Rapid’ infers prompt 
commencement of a csDMARD, commensurate with the severity 
of clinical presentation or comorbidities; delays should not 
exceed 2 weeks. Thus, while recommendation 4 has been newly 
added, it was already comprised in former recommendation 3, 
where ‘many swollen joints’ was mentioned as a poor prognostic 
marker requiring rapid (‘early’) institution of DMARDs.
This recommendation, as well as recommendation 5, places 
the use of csDMARDs in the management of PsA as first- line 
DMARDs. The continuous prioritisation of csDMARDs reflects 
consensual expert opinion within the taskforce that favoured the 
benefit to risk balance of csDMARDs and in particular MTX 
over biologicals, as well as their lower cost. Data supporting the 
use of MTX in PsA are scarce and include only small or inconclu-
sive clinical trials,37 as well as indirect evidence stemming from 
the TICOPA trial and evidence from observational studies.38–41 
However, the SEAM- PsA study, which was part of the SLR and 
has meanwhile been published in full, revealed that MTX has 
similar efficacy in joint counts, skin involvement, enthesitis, 
dactylitis and physical function as etanercept or even etaner-
cept plus MTX.42 Given this similarity of effectiveness, and the 
differences in costs, this study further supports the taskforce’s 
decision to place MTX and other csDMARDs at the top of the 
therapeutic algorithm (figure 1).
The taskforce acknowledged that patients may have a reluc-
tance to take MTX and may experience adverse effects. To our 
knowledge, data proving that MTX is less well tolerated in PsA 
than in rheumatoid arthritis are lacking, but the effects of and 
the overall long- term experience with MTX should be part of 
the information given to the patient in the process of shared 
decision- making.43 Thus far, MTX remains widely used in daily 
practice as reported in registries, has high treatment mainte-
nance over time and seems effective in the control arms of most 
clinical trials, in which disease control with MTX monotherapy 
appears satisfactory.42
MTX is highlighted among the csDMARDs, in particular for 
patients with ‘relevant’ skin involvement: ‘relevant’ is defined 
as either extensive (body surface area involvement >10%), or 
as important to the patient: more limited psoriasis leading to 
significant impact on quality of life (eg, face/hand/feet/genital 
involvement). This definition would correspond, in other 
dermatological terms, to moderate to severe psoriasis. MTX has 
proven efficacy in skin psoriasis, is recommended in treatment 
guidelines for psoriasis and has become the standard csDMARD 
for skin psoriasis in many countries.44–47
On the other hand, MTX leads to hepatotoxicity, and data on 
the beneficial effects of MTX on cardiovascular disease in PsA 
are conflicting.48 49 Taking all these elements into account, the 
taskforce felt a gradual approach to intensify PsA treatment most 
appropriate and proposed a csDMARD (usually MTX) as the 
first DMARD. MTX should be prescribed attempting to reach 
25 mg per week as the optimal dose and with folate supplemen-
tation. Other csDMARDs have shown efficacy in PsA as well and 
may also be considered at this stage (although with less efficacy 
in the skin): these include leflunomide and sulfasalazine.50 Ciclo-
sporin is not recommended for PsA.
If improvement does not exceed 50% of a composite measure 
for PsA within 3 months or the treatment target is not reached 
within 6 months, such csDMARD therapy should not be pursued 
longer (figure 1). In light of paucity of good clinical data, the 
search for better evidence for the efficacy of csDMARDs as 
monotherapy or as combination therapy was prioritised on the 
research agenda.
Recommendation 5: In patients with monoarthritis or oligoarthritis, 
particularly with poor prognostic factors such as structural damage, 
high erythrocyte sedimentation rate/c reactive protein, dactylitis or 
nail involvement, a csDMARD should be considered.
This recommendation emphasises that patients with oligoartic-
ular disease should (similar to polyarticular patients) receive a 
csDMARD rapidly in the presence of poor prognostic factors 
(please see the text of the recommendation). Concerning factors 
associated with poor prognosis (here defined as radiographic 
severity), the SLR identified nail involvement in addition to 
those factors presented in 2011 and 2015, and this element was 
added accordingly to the phrasing of recommendation 5.51 52
Dactylitis was previously addressed together with enthesitis 
(see recommendation 9 in 2015). However, these manifesta-
tions have now been separated. The taskforce considered that 
dactylitis was distinct in terms of physiopathology, diagnosis 
and prognosis, since it is linked to radiographic changes in PsA, 
whereas enthesitis is not.53 Furthermore, although there is a lack 
of good- quality data, recent studies suggest at least some efficacy 
of MTX in dactylitis.41 42 Thus, dactylitis should now be treated 
similarly to arthritis, and if associated with polyarticular disease 
it should be treated like polyarthritis. Of note, NSAIDs have not 
demonstrated efficacy in dactylitis.
Given the lack of strong data on oligoarticular PsA, this recom-
mendation was based more on expert opinion than on hard data 
(level of evidence, 4; grade of recommendation: C).
Recommendation 6: In patients with peripheral arthritis and an 
inadequate response to at least one csDMARD, therapy with a 
bDMARD should be commenced; when there is relevant skin 
involvement, an IL-17 inhibitor or IL-12/23 inhibitor may be 
preferred.
This recommendation addresses patients with peripheral 
arthritis, after failure or intolerance to at least one csDMARD. 
In these patients, the taskforce recommends a bDMARD. In 
some patients, especially those without bad prognostic factors or 
those with mild disease activity, it may be indicated to rotate to 
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a second csDMARD before starting a bDMARD, as previously 
outlined in the 2015 recommendations.12
The taskforce extensively discussed the legitimacy of a 
bDMARD as first DMARD strategy; the discussion focused on 
efficacy and safety, as well as on costs. The taskforce was of the 
opinion that many patients respond satisfactorily to MTX, while 
tolerating the drug well. These patients would be subjected to 
overtreatment if starting a bDMARD immediately rather than 
waiting for 3 months to determine if a response to MTX has 
occurred (see recommendations 9 and 10). A good example 
is revealed in the SEAM- PsA trial. However, if entheseal or 
axial inflammatory involvement predominates, earlier use of 
bDMARDs is proposed, since csDMARDs are ineffective in 
these conditions (please see recommendations 9 and 10).
Whereas the 2015 recommendation stated that it was ‘usual 
practice’ to start a TNFi in comparison with other bDMARDs, 
the current update does not distinguish anymore between TNFi, 
IL-12/23 inhibitor (IL-12/23i) and IL-17 inhibitor (IL- 17i). The 
SLR reconfirmed the efficacy of TNFi in PsA, and there are now 
reassuring long- term safety data with these drugs, including data 
indicating that the incidence of malignancies is not increased.54 55 
Drugs targeting IL-12/23 and IL-17 are also consistently efficacious 
in comparison with placebo and long- term safety seems favour-
able.1 In addition to secukinumab, a second IL- 17i, ixekizumab, 
has been approved since the 2015 recommendations, showing a 
similar efficacy and safety profile, which further reassured the task-
force.14 56 Importantly, a head- to- head trial of ixekizumab versus 
the TNFi adalimumab showed similar efficacy of ixekizumab and 
adalimumab for musculoskeletal manifestations.57
Of note, efficacy in joints appeared numerically less for the 
IL-12/23i ustekinumab; however, observational data indicate 
similar magnitudes of response versus TNFi, and a formal head- 
to- head trial is currently lacking.13 58 Furthermore, the taskforce 
noted that recent studies with biologicals targeting the IL-23- p19 
subunit (guselkumab, risankizumab, tildrakizumab) appear encour-
aging, and that targeting this pathway has shown excellent efficacy 
in psoriasis.59–63 Thus, a suggested order between different targeted 
pathways is intentionally not given in this recommendation.
The total safety picture of these three categories of bDMARDs 
appeared acceptable in our SLR.1 The risks of TNFi are well 
known from large registries for long- term safety including 
these drugs. IL- 17i may increase the incidence of (mild) local-
ised candidiasis, and monitoring for a possible increased risk of 
inflammatory bowel disease is still ongoing.64 In any case, safety 
must always be considered carefully in every patient; more 
complete information regarding the safety aspects of bDMARDs 
is provided in the drugs’ package inserts.
Taking together data on efficacy and safety, with regard to the 
treatment of arthritis in PsA, the taskforce found no reason to 
currently prioritise one of these bDMARDs over another one (as 
shown also in figure 1); costs should also be taken into account, 
and these may vary at the country level.
In contrast, both IL-12/23i and IL- 17i have shown greater effi-
cacy in skin than TNFi, in head- to- head trials of psoriasis and 
PsA62 65 66; this evidence justifies the second half of the recom-
mendation, which encourages the use of an IL-12/23i or IL- 17i in 
patients with relevant skin involvement, where ‘relevant’ is defined 
(as above) as either extensive or as important to the patient.
When choosing a first bDMARD, the differential impact 
on certain musculoskeletal and non- musculoskeletal manifes-
tations as well as comorbidities such as metabolic syndrome 
has to be considered. While important skin involvement was 
already mentioned, IL-12/23 inhibition may not be effective for 
axial involvement; IL-17 inhibition may not be appropriate for 
patients with concomitant inflammatory bowel disease for which 
monoclonal antibodies to TNF and IL-12/23 inhibitors are 
approved; and in the presence of uveitis, a monoclonal antibody 
to TNF may be the preferred first and second bDMARD because 
of respective approval.67 68 On the other hand, regarding comor-
bidities, the paucity of relevant data precludes firm recommen-
dations at present; this has been added to the research agenda.
The issue of monotherapy with bDMARDs versus combina-
tion therapy with a csDMARD was discussed.69 70 The current 
recommendation is to continue MTX with a bDMARD (using 
the latter as an add- on strategy) in patients already taking this 
drug and tolerating it well, but the taskforce admitted that to 
date there is no clear evidence that combination therapy is more 
efficacious than monotherapy, aside from a slight reduction of 
immunogenicity that is of doubtful clinical significance.71 We 
suggest that MTX dose may be reduced in subjects showing 
a good biological drug response, especially when there are 
concerns about MTX toxicity. However, more data are needed 
and this point was put into the research agenda.
Recommendation 7: In patients with peripheral arthritis and an 
inadequate response to at least one csDMARD and at least one 
bDMARD, or when a bDMARD is not appropriate, a JAK inhibitor 
may be considered.
At this moment, the only JAK inhibitor (JAKi) approved for 
PsA is tofacitinib. Our SLR indicated tofacitinib may have 
similar efficacy as the TNFi adalimumab for joint involvement, 
but numerically lower efficacy in skin psoriasis.1 15 72 There 
also appears to be satisfactory efficacy of tofacitinib in TNFi 
insufficient- responder populations.1 According to European 
Medicines Agency approval, tofacitinib must be prescribed with 
MTX. Safety signals exist for some infections, especially herpes 
zoster, as well as a recent signal for deep vein thrombosis espe-
cially with a high dose of tofacitinib which is not approved for 
PsA, but also the usual 5 mg twice daily dose particularly in those 
with cardiovascular risk factors and older patients.15 72 73
To date, two other JAKis are in development phases for PsA. 
Filgotinib showed promising efficacy in a phase II trial and upad-
acitinib was approved for use in rheumatoid arthritis shortly after 
the development of these recommendations, and also showed 
encouraging results in PsA.16
Taking these elements into account, as well as the general prin-
ciple of favouring drugs with robust long- term safety data, the task-
force proposed JAKi either after inadequate response or intolerance 
to at least one bDMARD, or when a bDMARD is considered not 
appropriate. ‘Not appropriate’ means, for example, non- adherence 
to injections or a strong patient preference for an oral drug (in 
accordance with the overarching principle A concerning ‘shared 
decision making’). However, the group agreed that normally the 
step- up approach would be a csDMARD followed by a bDMARD, 
and subsequently another bDMARD or a JAKi.
As new data become available, the current positioning of JAKis 
may evolve; this will justify an update of the recommendations if 
appropriate.
Recommendation 8: In patients with mild disease and an 
inadequate response to at least one csDMARD, in whom neither a 
bDMARD nor a JAK inhibitor is appropriate, a PDE4 inhibitor may be 
considered.
Similar to the 2015 update, this recommendation reserves 
a special place for apremilast: it should be used only when 
csDMARD therapy has failed and bDMARDs and JAKi are not 
appropriate; however, the taskforce considered that the value of 
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apremilast may be found in treating patients with relatively mild 
disease or those in whom other agents are contraindicated, such 
as in patients with chronic infections. Mild disease is defined here 
as only few joints (four or less, thus oligoarticular disease), lower 
disease activity by composite scores and/or limited skin involve-
ment. The reason for proposing the use of apremilast primarily 
for mild disease is that profound responses, such as Amercian 
College of Rheumatology 70% (ACR70), are rarely seen in 
clinical trials with apremilast and are sometimes not different 
from placebo.11 74–77 Moreover, radiographic data providing 
the disease- modifying potential of the drug are still lacking for 
apremilast, and therefore this drug may not be appropriate for 
patients with poor prognostic factors. A randomised controlled 
trial with apremilast in oligoarticular disease is currently under 
way.78
The level of agreement with this recommendation was lower 
than for the others, suggesting diverse expert views on the place 
of this drug.
Recommendation 9: In patients with unequivocal enthesitis and 
insufficient response to NsAIDs or local glucocorticoid injections, 
therapy with a bDMARD should be considered.
Compared with recommendation 8 of the 2015 version, ‘active 
enthesitis’ has been replaced by ‘unequivocal enthesitis’, and the 
last part stating that ‘current practice is to use a TNF- inhibitor’ 
has been omitted. In patients with enthesitis, NSAIDs and local 
glucocorticoids are the first- line treatment; in case of insufficient 
response, intolerance or contraindication to NSAIDs, and given 
that csDMARDs are not efficacious for enthesitis, a bDMARD 
(targeting TNF, IL-17 or IL-12/23) may be used. ‘Enthesitis’ here 
refers to inflammation rather than entheseal pain, and the term 
‘unequivocal’ has now been added to avoid overtreating trigger- 
point pain that has other underlying causes (such as concomitant 
widespread pain syndromes).79 While sonography or MRI may 
underpin the presence of enthesitis, clinical examination should 
in principle suffice, and the number and pattern (asymmetrical) 
of painful entheses, as well as the presence of clinical swelling, 
should guide the clinician and allow a distinction from wide-
spread pain syndromes.80–85 Entheseal disease is a complex issue 
in PsA and was also added to the research agenda.
Regarding bDMARDs, the taskforce now regards all bDMARDs 
as having efficacy of a similar magnitude for enthesitis and hence 
the preference for TNFi has been deleted.1
Recommendation 10: In patients with predominantly axial disease 
which is active and has insufficient response to NsAIDs, therapy 
with a bDMARD should be considered, which according to current 
practice is a tNF inhibitor; when there is relevant skin involvement, 
IL-17 inhibitor may be preferred.
In 2015, predominant (or highly significant) axial involvement 
was dealt with in recommendation 9. The phrasing of the current 
recommendation was partly aligned with the Assessment of 
Spondyloarthritis International Society (ASAS)/EULAR manage-
ment recommendations for axial spondyloarthritis (axSpA),35 
with the exception that these do not yet account for the use of 
IL- 17is. It also reflects that in the situation of predominantly 
axial disease, TNFi would still represent the first bDMARD by 
usual practice. The taskforce discussed that secukinumab has 
demonstrated efficacy in axSpA, and recently has demonstrated 
efficacy in patients considered to have predominant axial PsA.86 
However, the experience with IL-17 inhibition in terms of long- 
term efficacy and safety in axSpA and axial PsA is limited.
In predominantly axial PsA, in the presence of relevant skin 
involvement (as defined in the text below recommendation 4), 
an IL- 17i would be preferred over a TNFi, given the greater 
efficacy of IL- 17i in skin.57 Importantly, however, in case of 
concomitant inflammatory bowel disease or uveitis, a TNFi 
(monoclonal antibody) would be preferred.
Of note, the IL-12/23 pathway drugs did not demonstrate effi-
cacy in axSpA.87 Thus, in light of lack of clear efficacy, drugs 
targeting IL-12/23 and abatacept (see also recommendation 11) 
are not indicated for patients with predominantly axial disease.87
Recommendation 11: In patients who fail to respond adequately to, 
or are intolerant of a bDMARD, switching to another bDMARD or 
tsDMARD should be considered, including one switch within a class.
This recommendation, a slight expansion of the recommenda-
tion previously numbered as 10, addresses first bDMARD failure 
or intolerance. Here we propose a switch either to another 
bDMARD or to a tsDMARD, especially a JAKi. Novel data on 
switches are limited, with only one such new study found through 
the SLR.88 Trials performed in TNFi insufficient responders 
have demonstrated efficacy of bDMARDs with another mode 
of action when TNFi has failed.56 However, another TNFi can 
also be used, since no head- to- head trial data are available that 
suggest switching between classes is different from switching 
within class. Finally, the taskforce agreed that while switching 
within class was a viable option, it would be logical to change 
class after a second failure within a given class (expert opinion). 
Studies addressing the best possible strategy after failure(s) of 
bDMARDs other than TNFi are lacking to date, and this topic 
was added to the research agenda.
The taskforce discussed the place of abatacept, which has been 
approved for use in PsA, and considered abatacept’s place in the 
current algorithm should be limited to potential use after other 
bDMARDs have failed, given its relatively low efficacy.89
Recommendation 12: In patients in sustained remission, cautious 
tapering of DMARDs may be considered.
This is a new recommendation, primarily based on broad 
consensus among experts in the absence of solid trial data. 
Sparse data suggest a certain risk of relapse (either for joints 
or skin) when tapering.90–95 Still, the taskforce decided to offer 
guidance on tapering, since it was felt an important aspect of 
modern management, especially when sustained remission has 
been achieved, to mitigate treatment- related risks, to meet 
patients’ desires and demands, and to reduce cost of treatment.
Tapering was considered appropriate only in the context of 
sustained remission, defined here as complete remission (rather 
than low disease activity) for at least six consecutive months.32
This point was deliberately phrased tentatively, with a recom-
mendation to taper with great caution, as a consequence of shared 
decision- making based on comprehensive patient information. 
The recommendation does not have the intention to push clini-
cians towards stopping treatment but rather to try finding the 
smallest effective dose, either through dose reduction or interval 
lengthening. Best possible tapering strategies were also added as 
an item to the research agenda (table 3).
dIsCussIOn
Since the last update of these recommendations, new informa-
tion has accumulated on the efficacy and safety of established 
drugs and treatment strategies, but also on newer agents such 
as IL- 17is and IL-12/23is as well as JAKis. Thus, while these 
updated recommendations continue to integrate the established 
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as well as the new information, they also continue to attempt 
covering the broad spectrum of disease severity that best reflects 
clinical practice, in order to guide clinicians and other stake-
holders involved in treating patients with PsA with a simple algo-
rithm and set of recommendations that can easily be translated 
into daily clinical practice. Importantly, all of this information 
is based on a thorough SLR and on conclusions by an expert 
committee that primarily used evidence to derive its recom-
mendations, but also specialists’ opinions, where evidence was 
lacking or was insufficient.
These recommendations have been modified substantially 
compared with the 2015 update, since new drugs have entered 
the market and more evidence about existing drugs has accrued 
(table 2). In particular, longer term safety data have become avail-
able, which add importantly to the robustness of the evidence. 
In general this update adheres to the previous structure of these 
recommendations in all respects. (1) We continue to separate 
this guidance document into overarching (general) treatment 
approaches and individual therapeutic recommendations. (2) We 
continue to recommend targeting clinical remission (primarily 
for early disease) or, alternatively, low disease activity (for estab-
lished disease); in this light, a moderate let alone high disease 
activity state is unacceptable, unless comorbidities or other 
patient factors preclude treatment advances. (3) We continue 
to recommend a T2T strategy; the T2T recommendations have 
been recently updated and propose at least 50% improvement of 
the composite measure within 3 months and achievement of the 
target within 6 months from treatment initiation, thus requiring 
the use of a continuous measure of disease activity to follow 
patients longitudinally and also reflect patient perceptions. (4) 
As before, we structure the pathway to a successful outcome 
into four phases, an initial phase which might suffice in very 
mild disease or necessitate advancement to one of the next two 
phases; a second phase focusing on the use of csDMARDs; a 
third phase for patients who failed to reach the target in phase II 
and/or phase I when exhibiting predominant axial or entheseal 
disease; and a fourth phase for those who failed phase III.
Further, we provide a quantitative rather than only a quali-
tative assessment of the evidence available for all agents dealt 
with—not every drug that is approved must be assigned the same 
level of applicability if the database suggests differences, even 
if head- to- head trials are largely missing.57 In our view it is the 
task of expert committees to judge and qualify available data to 
the best of their knowledge for the best outcomes of the patients 
by interpreting the relevance of the available data after a thor-
ough debate and decision- making process. Thus, we weighed the 
evidence provided by the SLR in the course of the discussion 
and voting process. We aimed and aim at providing recommen-
dations that are not only truthful, but also have face validity and 
thus usefulness.
In preparing the recommendations, the taskforce adhered to 
the EULAR operating procedures for the development of recom-
mendations and assessed evidence levels according to the Oxford 
Evidence Based Medicine approach.21 22 Finally, the focus of this 
taskforce was on the musculoskeletal manifestations and, while 
mentioning the need to consult other specialists, these recom-
mendations, in line with the composition of the taskforce, are 
primarily aimed at rheumatologists and their patients with PsA. 
Recommendations for other specialists should be sought in the 
respective specialty literature.
Unlike other organisations that have also released treatment 
recommendations for PsA, EULAR has decided to not pursue 
Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) methodology for prioritising available 
treatments. While GRADE methodology is widely used and 
highly appreciated for properly judging quality of available 
evidence, experts within EULAR feel that GRADE puts too 
much emphasis on the methodology itself and tends to downplay 
prevalent but poorly investigated clinical scenarios for which 
clinicians still seek guidance. A good example of the latter is the 
place of MTX as first- line treatment: while we acknowledge the 
absence of good clinical evidence for MTX as first- line DMARD, 
we still recommend it as such, by virtue of long- term positive clin-
ical experience, including data from registries, as well as recent 
encouraging results, such as in the TICOPA and SEAM- PsA 
trials,42 long- term positive clinical experience, widespread fame 
and low treatment cost. We think this set of practical recommen-
dations, which has been developed according to general prin-
ciples of evidence- based medicine, will help rheumatologists in 
choosing the most appropriate and cost- effective drug treatment 
for every patient with PsA and in every clinical scenario, even 
though the body of scientific evidence may fall short in many 
aspects of the disease. We recognise the fields in which evidence 
is sparse or lacking are crucially important, and they frame the 
research agenda. We hope that clinical researchers will be influ-
enced by and appreciate the clinical questions summarised in 
the research agenda, and design experiments or trials aiming at 
providing resolution to these research questions.
All these aspects have allowed us to provide what the task-
force believes is the right place for the different drug classes in 
the treatment algorithm. Still, the EULAR PsA recommendations 
have preserved their original character which they share with 
other sets of EULAR recommendations for different inflam-
matory diseases. Important elements thereof are a graduated 
approach favouring well- known csDMARDs as first- line drugs 
and allowing escalation to bDMARDs when necessary; prefer-
ring drugs with an established long- term track record for safety 
over those that have recently been approved; and attention for 
tapering and stopping treatment if possible.
As before, the recommendations make it clear that one drug 
does not fit all and stipulate the role of the phenotypes and 
patient characteristics in the decision- making process of starting 
and stopping treatments. Shared decision- making has become 
an integral part of the management of patients with PsA. There 
is also more attention for ‘prognostic profiling’, paying more 
tribute to clinical reality; while the spectrum of patients with PsA 
included in trials is skewed towards patients with prognostically 
unfavourable polyarticular PsA, this type of PsA is a relatively 
rare condition in clinical practice, especially in the scenario of 
the initial early disease presentations in contemporary rheuma-
tology practice. Thus, recommendations should also give guid-
ance about how to address patients with milder oligoarticular or 
monoarticular disease.
Treatment decisions also have to take account of extramus-
culoskeletal disease manifestations such as inflammatory bowel 
disease or uveitis, aside from skin involvement, which require 
distinct therapies (anti- TNF monoclonal antibodies for uveitis, 
anti- TNF monoclonal antibodies or IL-12/23i for inflammatory 
bowel disease in the absence of axial involvement) just as they 
require distinct clinical evaluation. Importantly, these novel 
pieces of information only originated from the information that 
was obtained in the course of clinical trials of the various estab-
lished and new compounds.
As before, the updated recommendations have been 
summarised in an algorithm. The EULAR algorithm (figure 1) 
continues to account for the musculoskeletal diversity of PsA 
and should be easy to follow; where new therapies are partic-
ularly efficacious regarding skin involvement, a special note is 
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provided within the algorithm (see also respective footnotes), 
thus allowing to follow these management recommendations 
straightforwardly throughout the evolution of the disease.
In summary, the updated treatment recommendations for 
patients with PsA living in many different countries, under the 
influence of very different healthcare systems, support decision- 
making for the management of PsA and address the entire spec-
trum of the disease. An update will be needed within 2–4 years, 
as new data arise in PsA.
Author affiliations
1Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Sorbonne 
Universite, Paris, France
2APHP.Sorbonne Universite, Rheumatology Department, Hopital Universitaire Pitie 
Salpetriere, Paris, France
3Ruhr- Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany
4Division of Rheumatology, Department of Medicine 3; 2nd Department of Medicine, 
Hietzing Hospital, Medical University of Vienna, Vienna, Austria
5EULAR, Zurich, Switzerland
6Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, 
UK
7Hopital Cochin, Rheumatology, Université Paris Descartes, Paris, France
8Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, 
Sønderborg, Denmark
9Department of Regional Health Research, University of Southern Denmark, Odense, 
Denmark
10LTHT, Leeds NIHR Biomedical Research Centre, Leeds, UK
11Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 
Leeds, UK
12Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 
Vienna, Austria
13Research Center of Rheumatic Diseases, Sf Maria Hospital, Carol Davila University 
of Medicine and Pharmacy, Bucharest, Romania
143rd Department of Rheumatology, National Institute of Rheumatology and 
Physiotherapy, Budapest, Hungary
15Patient Research Partner, EULAR, Oslo, Norway
16Dermatology, University Hospitals of Geneva, Geneva, Switzerland
17Rheumatology and Clinical Immunology, Charite University Hospital Berlin, Berlin, 
Germany
18Arthritis Unit, Department of Rheumatology and IDIBAPS, Hospital Clinic, 
Barcelona, Spain
19Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia
20Department of Biomedicine, Aarhus University, Aarhus C, Denmark
21Department of Rheumatology, Aarhus Universitetshospital, Aarhus, Denmark
22Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
23Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands
24Rheumatology, Zuyderland MC, Heerlen, The Netherlands
25Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering 
Research Center, KU Leuven, Leuven, Flanders, Belgium
26Rheumatology, KU Leuven University Hospitals Leuven, Leuven, Flanders, Belgium
27Department of Rheumatology, Infectious Diseases and Rheumatology, Charité 
Universitätsmedizin Berlin, Berlin, Germany
28Epidemiology, German Rheumatism Research Center Berlin, Berlin, Germany
29Rheumatology, Hospital de Egas Moniz, Lisboa, Portugal
30Universidade Nova de Lisboa Centro de Estudos de Doencas Cronicas, Lisboa, 
Portugal
31Internal Medicine, University of Erlangen- Nuremberg, Erlangen, Germany
32Centre for Arthritis and Rheumatic Disease, Dublin Academic Medical Centre, St 
Vincent’s University Hospital, Dublin, Ireland
33Department of Internal Medicine and Pediatrics, VIB Center for Inflammation 
Research, Ghent University, Gent, Belgium
34Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
35Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 
Vienna, Wien, Austria
362nd Department of Medicine, Hietzing Hospital, Vienna, Wien, Austria
Twitter Tue Wenzel Kragstrup @KragstrupTW and Santiago Andres Rodrigues 
Manica @R_M_Santiago
Contributors All authors have contributed to this work and approved the final 
version.
Funding This study was funded by the European League Against Rheumatism. 
DMG and HM- O are supported by the National Institute for Health Research (NIHR) 
Leeds Biomedical Research Centre (LBRC). The views expressed are those of the 
authors and not necessarily those of the (UK) National Health Service (NHS), the 
NIHR or the (UK) Department of Health.
Competing interests LG: AbbVie, Biogen, Celgene, Janssen, Lilly, Mylan, Novartis, 
Pfizer, Sandoz, Sanofi- Aventis, UCB. XB: AbbVie, Amgen, BMS, Celgene, Chugai, 
Hexal, Janssen, Lilly, MSD, Mylan, Novartis, Pfizer, Sandoz, UCB. AK: Bristol- Myers 
Squibb, Celgene, Eli Lilly, Gilead, Merck Sharp and Dohme, Novartis, Pfizer. MdW: 
Through Stichting Tools from AbbVie, BMS, Celgene, Eli Lilly, Janssen- Cilag, Novartis, 
Pfizer, Roche. IM: AbbVie, BMS, Lilly, Novartis, Celgene, Gilead, Janssen, Boehringer, 
UCB, Pfizer. MD: AbbVie, BMS, Janssen, Lilly, Novartis, Merck, Pfizer, UCB. JP: BMS, 
Pfizer. DGM: AbbVie, BMS, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, UCB. 
DA: AbbVie, Amgen, Gilead, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi/
Genzyme, Sobi. AB: AbbVie, Amgen, AstraZeneca, Angelini, AlfaSigma, BMS, Berlin- 
Chemie, Egis, Ewopharma, GSK, Lilly, Mylan, MSD, Novartis, Pfizer, Roche, Sandoz, 
Sanofi, Teva, UCB, Zentiva. PVB: AbbVie, Celgene, Lilly, MSD, Novartis, Pfizer, Richter. 
HB: Pfizer. W- HB: AbbVie, Almirall, BMS, Celgene, Leo, Lilly, Novartis, Pfizer, UCB. 
GRB: AbbVie, Celgene, Lilly, MSD, Novartis, Pfizer. JDC: Celgene, Eli Lilly, Gilead, 
Janssen, Novartis, Pfizer, UCB. NSD: AbbVie, Boehringer Ingelheim, Gedeon Richter, 
Lilly, Novartis, Pfizer, Roche. TWK: Bristol- Myers Squibb, Eli Lilly, Novartis, Pfizer, 
UCB. TKK: AbbVie, Amgen, Biogen, BMS, Celltrion, Egis, Eli Lilly, Ewopharma, Hikma, 
Hospira/Pfizer, MSD, Mylan, Orion Pharma, Roche, Sandoz, Sanofi, UCB. RBML: 
AbbVie, Boehringer Ingelheim, Bristol- Myers Squibb, Celgene, Eli Lilly, Galapagos, 
Gilead, MSD, Novartis, Pfizer, UCB. RJUL is Director of Rheumatology Consultancy; 
AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB. HM- O: AbbVie, Celgene, Eli 
Lilly, Janssen, Novartis, Pfizer, Takeda, UCB. DP: AbbVie, BMS, Celgene, Janssen, Lilly, 
MSD, Novartis, Pfizer, Roche, UCB. SARM: Janssen, MSD, Novartis. GS: AbbVie, BMS, 
Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, UCB. DJV: AbbVie, Biogen, 
Boehringer Ingelheim, HealthBeacon, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, 
UCB. FEVdB: AbbVie, Celgene, Eli Lilly, Galapagos/Gilead, Janssen, Merck, Novartis, 
Pfizer, UCB. DvdH: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, 
Celgene, Cyxone, Daiichi, Eisai, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, 
Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma; Director 
of Imaging Rheumatology. JSS: grants to institution from AbbVie, AstraZeneca, 
Janssen, Lilly, Merck Sharp & Dohme, Pfizer and Roche; speaker for AbbVie, Amgen, 
AstraZeneca, Astro, Bristol- Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO 
Pharma, Janssen, Lilly, Merck Sharp & Dohme, Novartis- Sandoz, Pfizer, Roche, 
Samsung, Sanofi and UCB.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCId ids
Laure Gossec http:// orcid. org/ 0000- 0002- 4528- 310X
Andreas Kerschbaumer http:// orcid. org/ 0000- 0002- 6685- 8873
Maarten de Wit http:// orcid. org/ 0000- 0002- 8428- 6354
Jette Primdahl http:// orcid. org/ 0000- 0002- 1049- 4150
Juan D Canete http:// orcid. org/ 0000- 0001- 7932- 2632
Denis Poddubnyy http:// orcid. org/ 0000- 0002- 4537- 6015
Santiago Andres Rodrigues Manica http:// orcid. org/ 0000- 0002- 7217- 0469
Georg Schett http:// orcid. org/ 0000- 0001- 8740- 9615
Douglas J Veale http:// orcid. org/ 0000- 0003- 2802- 4971
Désirée van der Heijde http:// orcid. org/ 0000- 0002- 5781- 158X
RefeRences
 1 Kerschbaumer A, Smolen JS, Dougados M, et al. Pharmacological treatment of 
psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR 
recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016.
 2 Fernández-Carballido C, Martín-Martínez MA, García-Gómez C, et al. Impact of 
comorbidity on physical function in patients with ankylosing spondylitis and psoriatic 
arthritis attending rheumatology clinics. Results from the CAR diovascular in rheu MA 
tology (CARMA) study. Arthritis Care Res.
 3 Rodriguez- Moreno J, Bonet M, Del Blanco- Barnusell J, et al. Mutilating/resorptive 
arthritis. A study of 24 patients in a series of 360 patients with psoriatic arthritis. 
Reumatol Clin 2013;9:38–41.
 4 Ferguson LD, Siebert S, McInnes IB, et al. Cardiometabolic comorbidities in RA and 
PsA: lessons learned and future directions. Nat Rev Rheumatol 2019;15:461–74.
 5 Gudu T, Etcheto A, de Wit M, et al. Fatigue in psoriatic arthritis - a cross- sectional 
study of 246 patients from 13 countries. Joint Bone Spine 2016;83:439–43.
 6 Helliwell PS, Ruderman EM, History N. Natural history, prognosis, and socioeconomic 
aspects of psoriatic arthritis. Rheum Dis Clin North Am 2015;41:581–91.
 7 Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol 
2018;14:405–17.
- P

















is: first published as 10.1136/annrheum





711Gossec L, et al. Ann Rheum Dis 2020;79:700–712. doi:10.1136/annrheumdis-2020-217159
Recommendation
 8 Gossec L, de Wit M, Kiltz U, et al. A patient- derived and patient- reported outcome 
measure for assessing psoriatic arthritis: elaboration and preliminary validation of 
the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13- country EULAR 
initiative. Ann Rheum Dis 2014;73:1012–9.
 9 Desthieux C, Granger B, Balanescu AR, et al. Determinants of patient- physician 
discordance in global assessment in psoriatic arthritis: a multicenter European study. 
Arthritis Care Res 2017;69:1606–11.
 10 Orbai A- M, de Wit M, Mease P, et al. International patient and physician consensus 
on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis 
2017;76:673–80.
 11 Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled 
trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J 
Rheumatol 2016;43:1724–34.
 12 Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous 
golimumab in patients with active psoriatic arthritis: results through week twenty- four 
of the GO- VIBRANT study. Arthritis Rheumatol 2017;69:2151–61.
 13 Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti- IL-12/23 p40 
monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite 
conventional non- biological and biological anti- tumour necrosis factor therapy: 
6- month and 1- year results of the phase 3, multicentre, double- blind, placebo- 
controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990–9.
 14 Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin- 17A specific 
monoclonal antibody, for the treatment of biologic- naive patients with active psoriatic 
arthritis: results from the 24- week randomised, double- blind, placebo- controlled and 
active (adalimumab)- controlled period of the phase III trial SPIRIT- P1. Ann Rheum Dis 
2017;76:79–87.
 15 Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for 
psoriatic arthritis. N Engl J Med 2017;377:1537–50.
 16 Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective 
Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results 
from a randomised, placebo- controlled, phase 2 trial. Lancet 2018;392:2367–77.
 17 Gossec L, Smolen JS, Gaujoux- Viala C, et al. European League against rheumatism 
recommendations for the management of psoriatic arthritis with pharmacological 
therapies. Ann Rheum Dis 2012;71:4–12.
 18 Gossec L, Smolen JS, Ramiro S, et al. European League against rheumatism (EULAR) 
recommendations for the management of psoriatic arthritis with pharmacological 
therapies: 2015 update. Ann Rheum Dis 2016;75:499–510.
 19 Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of 
psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic 
arthritis. Arthritis Rheumatol 2016;68:1060–71.
 20 Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of 
Rheumatology/National psoriasis Foundation guideline for the treatment of psoriatic 
arthritis. Arthritis Rheumatol 2019;71:5–32.
 21 van der Heijde D, Aletaha D, Carmona L, et al. 2014 update of the EULAR 
standardised operating procedures for EULAR- endorsed recommendations. Ann 
Rheum Dis 2015;74:8–13.
 22 CEBM. Oxford centre for evidence- based Medicine—Levels of evidence (March 2009), 
2009. Available: https://www. cebm. net/ 2009/ 06/ oxford- centre- evidence- based- 
medicine- levels- evidence- march- 2009/
 23 Wendling D, Lukas C, Prati C, et al. 2018 update of French Society for rheumatology 
(SFR) recommendations about the everyday management of patients with 
spondyloarthritis. Joint Bone Spine 2018;85:275–84.
 24 Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin 
Arthritis Rheum 2017;47:351–60.
 25 Mitulescu TC, Popescu C, Naie A, et al. Acute anterior uveitis and other extra- articular 
manifestations of spondyloarthritis. J Med Life 2015;8:319–25.
 26 Peluso R, Iervolino S, Vitiello M, et al. Extra- Articular manifestations in psoriatic 
arthritis patients. Clin Rheumatol 2015;34:745–53.
 27 Siegel EL, Orbai A- M, Ritchlin CT. Targeting extra- articular manifestations in PSA: a 
closer look at enthesitis and dactylitis. Curr Opin Rheumatol 2015;27:111–7.
 28 Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular 
disease risk management in patients with rheumatoid arthritis and other forms of 
inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28.
 29 Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the 
likelihood of remission in rheumatoid arthritis and psoriatic arthritis? data from the 
prospective multicentre NOR- DMARD study. Ann Rheum Dis 2017;76:1906–10.
 30 Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 
2014 update of the recommendations of an international Task force. Ann Rheum Dis 
2016;75:3–15.
 31 Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing 
spondylitis and psoriatic arthritis, to target: recommendations of an international Task 
force. Ann Rheum Dis 2014;73:6–16.
 32 Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral 
spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of 
recommendations by an international Task force. Ann Rheum Dis 2018;77:3–17.
 33 Gorlier C, Orbai A- M, Puyraimond- Zemmour D, et al. Comparing patient- perceived 
and physician- perceived remission and low disease activity in psoriatic arthritis: an 
analysis of 410 patients from 14 countries. Ann Rheum Dis 2019;78:201–8.
 34 Gossec L, McGonagle D, Korotaeva T, et al. Minimal disease activity as a treatment 
target in psoriatic arthritis: a review of the literature. J Rheumatol 2018;45:6–13.
 35 van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS- EULAR 
management recommendations for axial spondyloarthritis. Ann Rheum Dis 
2017;76:978–91.
 36 Kalyoncu U, Bayindir Özün, Ferhat Öksüz M, et al. The psoriatic arthritis registry 
of turkey: results of a multicentre registry on 1081 patients. Rheumatology 
2017;56:279–86.
 37 Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo- controlled trial of 
methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368–77.
 38 Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in 
early psoriatic arthritis (TICOPA): a UK multicentre, open- label, randomised controlled 
trial. Lancet 2015;386:2489–98.
 39 Heiberg MS, Kaufmann C, Rødevand E, et al. The comparative effectiveness of 
anti- TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month 
results from a longitudinal, observational, multicentre study. Ann Rheum Dis 
2007;66:1038–42.
 40 Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one- year 
performance of anti- tumor necrosis factor alpha drugs in patients with rheumatoid 
arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, 
observational, multicenter study. Arthritis Rheum 2008;59:234–40.
 41 Lie E, van der Heijde D, Uhlig T, et al. Effectiveness and retention rates of 
methotrexate in psoriatic arthritis in comparison with methotrexate- treated patients 
with rheumatoid arthritis. Ann Rheum Dis 2010;69:671–6.
 42 Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as 
monotherapy or in combination for psoriatic arthritis: primary results from a 
randomized, controlled phase III trial. Arthritis Rheumatol 2019;71:1112–24.
 43 Nikiphorou E, Negoescu A, Fitzpatrick JD, et al. Indispensable or intolerable? 
methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective 
review of discontinuation rates from a large UK cohort. Clin Rheumatol 
2014;33:609–14.
 44 Carrascosa JM, de la Cueva P, Ara M, et al. Methotrexate in moderate to severe 
psoriasis: review of the literature and expert recommendations. Actas Dermosifiliogr 
2016;107:194–206.
 45 Menter A, Gelfand JM, Connor C, et al. Joint AAD- NPF guidelines of care for the 
management of psoriasis with systemic non- biological therapies. J Am Acad Dermatol 
2020;9622.
 46 SmithKC. Systemic therapy of psoriasis using methotrexate. Skin Therapy Lett 
2000;6:1-2; 5.
 47 Armstrong AW, Betts KA, Sundaram M, et al. Comparative efficacy and incremental 
cost per Responder of methotrexate versus apremilast for methotrexate- naïve patients 
with psoriasis. J Am Acad Dermatol 2016;75:740–6.
 48 Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with 
psoriatic arthritis, psoriasis and rheumatoid arthritis: a population- based cohort study. 
Ann Rheum Dis 2015;74:326–32.
 49 Li L, Hagberg KW, Peng M, et al. Rates of cardiovascular disease and major adverse 
cardiovascular events in patients with psoriatic arthritis compared to patients without 
psoriatic arthritis. JCR: Journal of Clinical Rheumatology 2015;21:405–10.
 50 Ramiro S, Smolen JS, Landewé R, et al. Pharmacological treatment of psoriatic 
arthritis: a systematic literature review for the 2015 update of the EULAR 
recommendations for the management of psoriatic arthritis. Ann Rheum Dis 
2016;75:490–8.
 51 Jadon DR, Shaddick G, Tillett W, et al. Psoriatic arthritis mutilans: characteristics and 
natural radiographic history. J Rheumatol 2015;42:1169–76.
 52 El Miedany Y, El Gaafary M, Youssef S, et al. Tailored approach to early psoriatic 
arthritis patients: clinical and ultrasonographic predictors for structural joint damage. 
Clin Rheumatol 2015;34:307–13.
 53 Geijer M, Lindqvist U, Husmark T, et al. The Swedish early psoriatic arthritis registry 
5- year followup: substantial radiographic progression mainly in men with high disease 
activity and development of Dactylitis. J Rheumatol 2015;42:2110–7.
 54 Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis 
treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO 
registers. Ann Rheum Dis 2017;76:105–11.
 55 Costa L, Caso F, Del Puente A, et al. Incidence of malignancies in a cohort of 
psoriatic arthritis patients taking traditional disease modifying antirheumatic drug 
and tumor necrosis factor inhibitor therapy: an observational study. J Rheumatol 
2016;43:2149–54.
 56 Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with 
active psoriatic arthritis and an inadequate response to tumour necrosis factor 
inhibitors: results from the 24- week randomised, double- blind, placebo- controlled 
period of the SPIRIT- P2 phase 3 trial. The Lancet 2017;389:2317–27.
 57 Mease PJ, Smolen JS, Behrens F, et al. A head- to- head comparison of the efficacy 
and safety of ixekizumab and adalimumab in biological- naïve patients with active 
psoriatic arthritis: 24- week results of a randomised, open- label, blinded- assessor trial. 
Ann Rheum Dis 2020;79:123–31.
 58 McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in 
patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, 
double- blind, placebo- controlled PSUMMIT 1 trial. Lancet 2013;382:780–9.
- P

















is: first published as 10.1136/annrheum





712 Gossec L, et al. Ann Rheum Dis 2020;79:700–712. doi:10.1136/annrheumdis-2020-217159
Recommendation
 59 Deodhar A, Gottlieb AB, Boehncke W- H, et al. Efficacy and safety of guselkumab in 
patients with active psoriatic arthritis: a randomised, double- blind, placebo- controlled, 
phase 2 study. Lancet 2018;391:2213–24.
 60 Mease PJ, Kellner H, Morita A, et al. OP0307 efficacy and safety of risankizumab, a 
selective IL- 23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: 
results from a phase 2 trial. Ann Rheum Dis 2018;77:200–1.
 61 Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti- 
interleukin-23 monoclonal antibody, compared with adalimumab for the continuous 
treatment of patients with moderate to severe psoriasis: results from the phase III, 
double- blinded, placebo- and active comparator- controlled voyage 1 trial. J Am Acad 
Dermatol 2017;76:405–17.
 62 Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti- 
interleukin-23 monoclonal antibody, compared with adalimumab for the treatment 
of patients with moderate to severe psoriasis with randomized withdrawal and 
retreatment: results from the phase III, double- blind, placebo- and active comparator- 
controlled voyage 2 trial. J Am Acad Dermatol 2017;76:418–31.
 63 Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in 
moderate- to- severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two 
double- blind, randomised, placebo- controlled and ustekinumab- controlled phase 3 
trials. Lancet 2018;392:650–61.
 64 Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained 
improvements in the signs and symptoms of psoriatic arthritis: final 5- year results 
from the phase 3 future 1 study. ACR Open Rheumatol 2020;2:18–25.
 65 Blauvelt A, Reich K, Tsai T- F, et al. Secukinumab is superior to ustekinumab in clearing 
skin of subjects with moderate- to- severe plaque psoriasis up to 1 year: Results from 
the CLEAR study. J Am Acad Dermatol 2017;76:e69:60–9.
 66 Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for 
moderate- to- severe plaque psoriasis. N Engl J Med 2017;376:1551–60.
 67 Schreiber S, Colombel J- F, Feagan BG, et al. Incidence rates of inflammatory bowel 
disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated 
with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann 
Rheum Dis 2019;78:473–9.
 68 So A, Inman RD. An overview of biologic disease- modifying antirheumatic drugs 
in axial spondyloarthritis and psoriatic arthritis. Best Pract Res Clin Rheumatol 
2018;32:453–71.
 69 Aaltonen K, Heinonen A, Joensuu J, et al. Effectiveness and drug survival of TNF- 
inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin 
Arthritis Rheum 2017;46:732–9.
 70 Behrens F, Cañete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs 
combination with MTX in the treatment of PSA: a systematic review of the literature. 
Rheumatology 2015;54:915–26.
 71 Zisapel M, Zisman D, Madar- Balakirski N, et al. Prevalence of TNF-α blocker 
immunogenicity in psoriatic arthritis. J Rheumatol 2015;42:73–8.
 72 Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients 
with an inadequate response to TNF inhibitors. N Engl J Med 2017;377:1525–36.
 73 Ema confirms Xeljanz to be used with caution in patients at high risk of blood clots. 
Available: https://www. ema. europa. eu/ en/ news/ ema- confirms- xeljanz- be- used- 
caution- patients- high- risk- blood- clots [Accessed 2 Apr 2020].
 74 Kavanaugh A, Mease PJ, Gomez- Reino JJ, et al. Treatment of psoriatic arthritis 
in a phase 3 randomised, placebo- controlled trial with apremilast, an oral 
phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020–6.
 75 Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 
inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, 
randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016;75:1065–73.
 76 Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD- naive 
psoriatic arthritis patients: results of the randomized, placebo- controlled PALACE 4 
trial. Rheumatology 2018;57:1253–63.
 77 Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast 
monotherapy in biological- naïve patients with psoriatic arthritis: a phase IIIB, 
randomised controlled trial (active). Ann Rheum Dis 2018;77:690–8.
 78  ClinicalTrials. gov. Efficacy, safety, and tolerability study of apremilast to treat 
early Oligoarticular psoriatic arthritis. Available: https:// clinicaltrials. gov/ ct2/ show/ 
NCT03747939
 79 Fan A, Pereira B, Tournadre A, et al. Frequency of concomitant fibromyalgia in 
rheumatic diseases: monocentric study of 691 patients. Semin Arthritis Rheum 
2017;47:129–32.
 80 Kaeley GS, Eder L, Aydin SZ, et al. Enthesitis: a hallmark of psoriatic arthritis. Semin 
Arthritis Rheum 2018;48:35–43.
 81 Marchesoni A, De Marco G, Merashli M, et al. The problem in differentiation 
between psoriatic- related polyenthesitis and fibromyalgia. Rheumatology 
2018;57:32–40.
 82 Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and 
patient- reported outcomes in psoriatic arthritis patients with Dactylitis or Enthesitis: 
results from the Corrona psoriatic Arthritis/Spondyloarthritis registry. Arthritis Care 
Res 2017;69:1692–9.
 83 Polachek A, Cook R, Chandran V, et al. The association between sonographic 
enthesitis and radiographic damage in psoriatic arthritis. Arthritis Res Ther 
2017;19:189.
 84 Polachek A, Li S, Chandran V, et al. Clinical Enthesitis in a prospective longitudinal 
psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis 
Care Res 2017;69:1685–91.
 85 Schett G, Lories RJ, D’Agostino M- A, et al. Enthesitis: from pathophysiology to 
treatment. Nat Rev Rheumatol 2017;13:731–41.
 86 Baraliakos X, Coates LC, Gossec L. Secukinumab improves axial manifestations in 
patients with psoriatic arthritis and inadequate response to NSAIDs: primary analysis 
of phase 3 trial. Atlanta, Georgia, USA: ACR/ARP Annual Meeting, 2019.
 87 Siebert S, Millar NL, McInnes IB. Why did IL- 23p19 inhibition fail in as: a tale of 
tissues, trials or translation? Ann Rheum Dis 2019;78:1015–8.
 88 Kristensen LE, Lie E, Jacobsson LTH, et al. Effectiveness and feasibility associated 
with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a 
cohort study from southern Sweden. J Rheumatol 2016;43:81–7.
 89 Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a 
T- cell modulator, in a randomised, double- blind, placebo- controlled, phase III study in 
psoriatic arthritis. Ann Rheum Dis 2017;76:1550–8.
 90 Moverley A, Coates L, Marzo- Ortega H, et al. A feasibility study for a randomised 
controlled trial of treatment withdrawal in psoriatic arthritis (removal of treatment 
for patients in remission in psoriatic arthritis (retreat (F)). Clin Rheumatol 
2015;34:1407–12.
 91 Cantini F, Niccoli L, Nannini C, et al. Frequency and duration of clinical remission in 
patients with peripheral psoriatic arthritis requiring second- line drugs. Rheumatology 
2008;47:872–6.
 92 Araujo EG, Finzel S, Englbrecht M, et al. High incidence of disease recurrence after 
discontinuation of disease- modifying antirheumatic drug treatment in patients with 
psoriatic arthritis in remission. Ann Rheum Dis 2015;74:655–60.
 93 Chimenti MS, Esposito M, Giunta A, et al. Remission of psoriatic arthritis after 
etanercept discontinuation: analysis of patients’ clinical characteristics leading to 
disease relapse. Int J Immunopathol Pharmacol 2013;26:833–8.
 94 Janta I, Martínez- Estupiñán L, Valor L, et al. Comparison between full and tapered 
dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound 
assessment. Clin Rheumatol 2015;34:935–42.
 95 Mease P. Is reduction or discontinuation of therapy an acceptable possibility in 
psoriatic arthritis? Clin Exp Rheumatol 2013;31:S59–62.
- P

















is: first published as 10.1136/annrheum
dis-2020-217159 on 20 M
ay 2020. D
ow
nloaded from
 
